The executive has 12+ years of experience with downstream process development, optimization, characterization, scale-up, and tech transfer of in-vitro transcribed mRNA and lipid nanoparticles (LNPs). The executive has experience at Intellia and is current a customer of Trilink at Beam Therapeutics.
... (transcript preview, sign up to read more) ...
... (transcript preview, sign up to read more) ...
It's not that simple because you have to navigate the IP space, and the ability to do that chemical synthesis and purification is a very high upfront investment, to have those capabilities established in-house. You can have a vessel with enzymatic reaction, but if you start going into the chemistry of that, that in itself has a whole layer of build out and upfront costs associated with those. Unless you're big pharma that has the capabilities, that's not something you can in-source, so to speak. Even then, you still have to navigate the IP space, so you can't simply build the same structure.
... (transcript preview, sign up to read more) ...
The executive has 12+ years of experience with downstream process development, optimization, characterization, scale-up, and tech transfer of in-vitro transcribed mRNA and lipid nanoparticles (LNPs). The executive has experience at Intellia and is current a customer of Trilink at Beam Therapeutics.
Subscribe to access hundreds of interviews and primary research